Zepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...

New research indicates sleep apnea patients who use CPAP machines might face increased risk of heart attack, stroke and other ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

Sleep apnea is a condition where breathing repeatedly stops or reduces during sleep, often due to airway obstruction. It ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Alzheimer's disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing during sleep ...

DelveInsight’s, “Sleep Apnea Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 14+ pipeline drugs in Sleep Apnea pipeline landscape. It covers the Sleep Apnea ...

Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that address the root causes of obstructive sleep apnea (OSA) and other sleep-related ...

Fatty liver and insulin resistance go hand in hand. When the liver is overloaded with fat, it becomes less responsive to ...